BML Capital Management, LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
BML Capital Management, LLC disclosed 25 US equity positions worth $161.0m in its Q4 2024 13F filing. The largest position was ACRS at 22.0% of the reported book, followed by SGOV and AVIR. Against the Q3 2024 filing, it opened 4 new positions, added to 7 and reduced 5 among the top 25 holdings.
What did BML Capital Management, LLC own in Q4 2024? Top 25 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 22.0% | $35.3m | 14,250,000 | 0% | held |
| 2 | SGOV ISHARES TR | 16.2% | $26.1m | 260,000 | -4% | reduced | |
| 3 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 15.8% | $25.5m | 7,608,312 | 14% | added |
| 4 | AVU0 ADVERUM BIOTECHNOLOGIES INC | 6.6% | $10.6m | 2,268,064 | 0% | held | |
| 5 | ANTX AN2 THERAPEUTICS INC | 4.9% | $7.9m | 5,749,432 | 0% | held | |
| 6 | TIL INSTIL BIO INC | 4.7% | $7.6m | 400,000 | 19% | added | |
| 7 | EPIEUR ESSA PHARMA INC | 4.7% | $7.6m | 4,221,546 | – | new | |
| 8 | WHWK AADI BIOSCIENCE INC | Healthcare | 4.1% | $6.6m | 2,100,000 | 5% | added |
| 9 | ORMP ORAMED PHARMACEUTICALS INC | 4.0% | $6.4m | 2,643,907 | 21% | added | |
| 10 | IKENA ONCOLOGY INC | 3.7% | $5.9m | 3,585,866 | 396% | added | |
| 11 | PMVP PMV PHARMACEUTICALS INC | 3.3% | $5.2m | 3,466,684 | 105% | added | |
| 12 | 698 ACHILLES THERAPEUTICS PLC | 2.9% | $4.7m | 4,100,002 | 0% | held | |
| 13 | CNTB CONNECT BIOPHARMA HLDGS LTD | 1.8% | $2.9m | 2,093,232 | 0% | held | |
| 14 | MIST MILESTONE PHARMACEUTICALS IN | 1.7% | $2.7m | 1,136,091 | 0% | held | |
| 15 | ATHIRA PHARMA INC | 1.0% | $1.6m | 2,775,885 | – | new | |
| 16 | ASTROTECH CORP | 0.9% | $1.5m | 220,410 | 0% | held | |
| 17 | LSTA LISATA THERAPEUTICS INC | 0.5% | $848.3k | 284,669 | 0% | held | |
| 18 | PVLA PALVELLA THERAPEUTICS INC NE | 0.3% | $505.6k | 42,130 | – | new | |
| 19 | VTGN VISTAGEN THERAPEUTICS INC | 0.3% | $442.5k | 150,000 | 0% | held | |
| 20 | 2KZ0 KEZAR LIFE SCIENCES INC | 0.2% | $327.0k | 48,668 | – | new | |
| 21 | LENZ LENZ THERAPEUTICS INC | Healthcare | 0.2% | $267.7k | 9,271 | -85% | reduced |
| 22 | NXTC NEXTCURE INC | 0.1% | $210.9k | 273,536 | -1% | reduced | |
| 23 | VRCA VERRICA PHARMACEUTICALS INC | 0.1% | $122.3k | 174,651 | -3% | reduced | |
| 24 | ALLOVIR INC | 0.0% | $77.4k | 184,246 | -69% | reduced | |
| 25 | HILLEVAX INC | 0.0% | $43.0k | 20,760 | 5% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.